Advanced Clinical Research Network Corp — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$465,403	118
2024	Research	$43,250	12
2023	Research	$21,311	3
2022	Research	$54,652	1
2021	Research	$20,456	3
2020	Research	$17,984	4
2019	Research	$76,031	12

Breakdown

Who paid Research payments · program years 2019–2025

ACADIA Pharmaceuticals Inc $325,308 56 payments
ITI, Inc. $149,293 63 payments
Otsuka Pharmaceutical Development & Commercialization, Inc. $133,140 7 payments
Takeda Pharmaceuticals U.S.A., Inc. $62,348 15 payments
Sanofi US Services Inc. $28,997 12 payments

Studies the money was for Research payments · program years 2019–2025

Acp-204-012 $186,164 25 payments
Iti-1284-101 $149,293 63 payments
Acp-204-006 $76,982 13 payments
Acp-204-008 $62,162 18 payments
A Phase 3 Long-Term Safety Extension Study of Shp647 in Subjects With Moderate to Severe Ulcerative Colitis (Aida) $58,396 14 payments
A Phase 3, 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Fixed-Dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (Opc-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimers Type $55,652 2 payments
A Phase 3, 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Fixed-Dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole Opc34712 in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimers Type $41,166 1 payment
A 12-Week, Multicenter, Active-Treatment Extension Trial to Evaulate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type $19,278 2 payments
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi $12,608 3 payments
A 12-Week, Multicenter, Active-Treatment Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type $12,470 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.